Clinical trials: Adjuvant Drug Therapy
Breast Cancer, Rehabilitation
Prehabilitation for Women Undergoing Pre-operative Chemotherapy for Breast Cancer
To assess recruitment rate, attrition, compliance with weekly exercise, smoking cessation, and quality of life with a multimodal prehabilitation protocol for women with breast cancer undergoing neo-adjuvant chemotherapy for…
- Conditions
- Breast Cancer, Rehabilitation, Neoadjuvant Therapy, Feasibility Studies
- Trial name
- NCT03564171
- Testing
- Prehabilitation
- Where
- Canada
- Volunteers
- 63 people
- Sponsor
- Sunnybrook Health Sciences Centre
Breast Cancer
Neoadjuvant Effect of Albumin Binding Paclitaxel Compared With Common Paclitaxel in Breast Cancer：an Observational Single Center Study of Clinical Efficacy in Adjuvant Chemotherapy
In recent years, the incidence rate of breast cancer has remained high. In China, breast cancer is the malignant tumor with the highest incidence rate among women.
- Trial name
- NCT05636644
- Testing
- Taxol
- Where
- China
- Volunteers
- 112 people
- Sponsor
- Mei Zhang
Colon Cancer Stage III
Randomized Study on Adjuvant Chemotherapy and Adjuvant Chemo-Immunotherapy in Colon Carcinoma Dukes C
This clinical investigation examined the effectivity 5-fluorouracil, of adding levamisol or interferon to 5-fluorouracil, and of a 5-fluorouracil/levamisol/interferon triple combination, in terms of recurrence-free and overall…
- Trial name
- NCT00309530
- Testing
- 5-fluorouracil, levamisol, interferon
- Where
- 16 sites in Austria
- Volunteers
- 598 people
- Sponsor
- Austrian Breast & Colorectal Cancer Study Group
Breast Cancer
4 x Epirubicin, Cyclophosphamide, Followed by 4 x Docetaxel Versus 6 x CMF / 6 x CEF
Taxane-based adjuvant chemotherapy is standard in node-positive (N+) early breast cancer (BC). The magnitude of benefit in intermediate-risk N+ early BC is still unclear.
- Trial name
- NCT02115204
- Testing
- Epirubicin, Cyclophosphamide, Docetaxel
- Where
- Germany
- Volunteers
- 2,011 people
- Sponsor
- Women's Cancer Study Group GmbH
Gastric Cancer
Docetaxel+Oxaliplatin+S-1 (DOS) Regimen as Neoadjuvant Chemotherapy in Advanced Gastric Cancer
Primary Objective: To compare the 3-year progression free survival (PFS) in the two treatment arms. Secondary Objectives: Overall survival (OS). Postoperative pathological stage and R0 (complete) resection rate.
- Trial name
- PRODIGY (NCT01515748)
- Testing
- Docetaxel (XRP6976), Oxaliplatin (SR96669), S-1 (1-(2-tetrahydrofuryl)-5-fluorouracil + 5-chloro-2, 4-dihydroxypyridine (CDHP) (Gimeracil) + Oxo (Oteracil)
- Where
- South Korea
- Volunteers
- 530 people
- Sponsor
- Sanofi
Breast Cancer
A Study to Evaluate Ethanol-induced Symptoms and Safety in Breast Cancer Patients
The purpose of this study is to evaluate ethanol-induced symptoms and safety in breast cancer patients with neoadjuvant/adjuvant chemotherapy including Non-ethanol formulation docetaxel before and after surgery
- Trial name
- NCT06537752
- Where
- 2 sites in South Korea
- Volunteers
- 1,052 people
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Breast Cancer
A Study of Dato-DXd With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Without Pathological Complete Response Following Neoadjuvant Therapy (TROPION-Breast03)
This is a Phase III, randomized, open-label, 3-arm, multicenter, international study assessing the efficacy and safety of Dato-DXd with or without durvalumab compared with ICT in participants with stage I to III TNBC with…
- Trial name
- NCT05629585
- Testing
- Dato-DXd, Durvalumab, Capecitabine
- Where
- 276 sites in United States, Belgium and 15 more
- Volunteers
- 1,174 people
- Sponsor
- AstraZeneca
Pancreatic Ductal Adenocarcinoma
A Study of ASP2138 Given Before Surgery, Then Chemotherapy After Surgery, in People With Pancreatic Ductal Cancer
Some people with pancreatic ductal cancer (PDAC) have a protein called Claudin 18.2 (CLDN18.2) in their tumor. ASP2138 is thought to work by binding to CLDN18.2 and a protein on a type of immune cell called a T-cell.
- Trial name
- NCT07024615
- Testing
- ASP2138, Oxaliplatin, Leucovorin
- Where
- 3 sites in United States
- Volunteers
- 25 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Breast Neoplasm
Phase II Trial to Compare the Safety of Two Chemotherapy Plus Trastuzumab Regimens as Adjuvant Therapy for HER2-positive Breast Cancer (Study P05048)
The purpose of this study is to compare the incidence of cardiac dysfunction in subjects with human epidermal growth factor receptor 2 (HER2) positive breast cancer treated with either doxorubicin or pegylated liposomal…
- Trial name
- NCT00550771
- Testing
- doxorubicin, cyclophosphamide, paclitaxel, trastuzumab, PLD, cyclophosphamide, trastuzumab, paclitaxel
- Volunteers
- 181 people
- Sponsor
- Merck Sharp & Dohme LLC
Medication Adherence, Breast Cancer
Adjuvant Endocrine Therapy Adherence Intervention Pilot in Rwanda
This study aims to evaluate a multi-modal intervention designed to improve adherence to adjuvant endocrine therapy (AET) among patients with ER-positive breast cancer in Rwanda.
- Trial name
- NCT07562399
- Testing
- Educational video, Symptom monitoring card, Text reminders
- Where
- 4 sites in United States, Rwanda
- Volunteers
- 224 people
- Sponsor
- Dana-Farber Cancer Institute
Breast Neoplasms
Aromasin® Interventional Study Of Early Invasive Breast Cancer Patients In China
Aromasin® (Exemestane) was approved in China for adjuvant treatment of postmenopausal women with estrogen receptor (ER) positive early invasive breast cancer who have received 2-3 years of tamoxifen \& are switched to Aromasin®…
- Trial name
- NCT01176916
- Testing
- Aromasin (exemestane)
- Where
- 53 sites in China
- Volunteers
- 564 people
- Sponsor
- Pfizer
Pancreatic Cancer
Study of Pancreatic Enzyme Replacement on Completion of Adjuvant Chemotherapy for Resected Pancreatic Adenocarcinoma
This research study is evaluating a study drug to treat pancreatic exocrine insufficiency (PEI) during the first year after the diagnosis of pancreatic cancer while the participant is recovering from surgery and receiving…
- Trial name
- NCT03469258
- Testing
- Pancrelipase
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Dana-Farber Cancer Institute
Gastric Cancer
A Feasibility Study to Evaluate Adjuvant Chemoradiotherapy for Gastric Cancer
The purpose of this study is to determine the side-effects and effectiveness of a new type of chemoradiotherapy treatment for patients who have had surgery for stomach cancer.
- Trial name
- NCT00123318
- Testing
- epirubicin, cisplatin, 5-fluorouracil
- Where
- 19 sites in Australia, New Zealand
- Volunteers
- 52 people
- Sponsor
- Trans Tasman Radiation Oncology Group
Staged III Colorectal Cancer Receiving Adjuvant Chemotherapy
Oral Lactobacillus Rhamnosus TCELL-1 and Colorectal Cancer
Emerging evidences have shown that gut microbiota have played roles in the modulation of chemotherapy agents for cancer patients receiving chemotherapy. Probiotics are gut microbiota beneficial to human body.
- Trial name
- NCT05570942
- Testing
- Oral Lactobacillus rhamnosus TCELL-1
- Where
- Taiwan
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- National Taiwan University Hospital
Periampullary Adenocarcinoma, Periampullary Cancer
Chemotherapy, Host Response and Molecular Dynamics in Periampullary Cancer
The CHAMP (Chemotherapy, Host response And Molecular dynamics in Periampullary cancer) study is a prospective, single-arm observational study that started Sept 1 2018.
- Conditions
- Periampullary Adenocarcinoma, Periampullary Cancer, Pancreatic Cancer
- Trial name
- CHAMP (NCT03724994)
- Testing
- Gemcitabine
- Where
- Sweden
- Volunteers
- 201 people
- Sponsor
- Lund University
Gastric and Esophagogastric Junction Adenocarcinoma
Postoperative Immunotherapy vs Standard Chemotherapy for Gastric Cancer With High Risk for Recurrence
The primary objective of the trial is to investigate if nivolumab plus ipilimumab given as adjuvant treatment improve disease free survival (DFS) in patients with stage Ib-IVa gastric and esophagogastric junction adenocarcinoma…
- Trial name
- VESTIGE (NCT03443856)
- Testing
- Nivolumab and Ipilimumab, chemotherapy
- Where
- 28 sites in Czechia, France and 7 more
- Volunteers
- 197 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Gastric Cancer, Stomach Cancer
Pre-operation Chemo and Antibody Therapy Followed by Surgical Resection and Adjuvant Chemoradiation for Gastric Cancer
This study intends to evaluate the feasibility and treatment efficacy of adding an antibody blocking the epidermal growth factor (EGF) pathway to a neoadjuvant approach with proven efficacy developed at New York University.
- Trial name
- NCT00857246
- Testing
- Cetuximab, Irinotecan, Cisplatin
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- NYU Langone Health
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8
Identifying Decision Making Needs for Older Adult Women With Stage I-III Breast Cancer Considering Neoadjuvant or Adjuvant Chemotherapy
This study collects information and identifies decision making needs for older adult women with stage I-III breast cancer considering neoadjuvant and adjuvant chemotherapy.
- Conditions
- Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8
- Trial name
- NCT05049746
- Testing
- Discussion, Interview, Questionnaire Administration
- Where
- United States
- Volunteers
- 95 people, healthy volunteers welcome
- Sponsor
- M.D. Anderson Cancer Center
Colorectal Cancer
Study of Tumor Samples From Patients With Stage III Colon Cancer Who Have Undergone Surgery and Chemotherapy
RATIONALE: Studying samples of tumor tissue in the laboratory from patients with cancer who have undergone surgery and chemotherapy may help doctors predict how well patients will respond to treatment.
- Trial name
- NCT00918827
- Where
- Japan
- Volunteers
- 2,128 people
- Sponsor
- Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan
Breast Cancer
A Study to Evaluate Vinorelbine Plus Capecitabine Combined With Trastuzumab for HER2 Positive Patients Following Neoadjuvant Chemotherapy
This study aims to evaluate vinorelbine plus capecitabine combined with trastuzumab versus trastuzumab alone as the adjuvant Treatment of HER2 positive patients following neoadjuvant chemotherapy
- Trial name
- NCT04302441
- Testing
- Vinorelbine, Capecitabine
- Where
- China
- Volunteers
- 550 people
- Sponsor
- Fudan University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.